© 2017 Pharmstandard Ventures
Inbio Ventures Joins the Syndicated $18 Million Investment in Protagonist Therapeutics
12.08.2013
Moscow – August 09, 2013 – Inbio ventures, a management company representing Pharmstandard International S.A., has joined the Series B financing for Protagonist Therapeutics Inc., operating in Menlo Park, CA, USA, and Brisbane, Queensland, Australia.
The financing, led by Johnson & Johnson Development Corporation (JJDC), also included the participation of Series A investors Lilly Ventures and Starfish Ventures (Melbourne, Australia).The new funding will support the discovery and development of Protagonist's pipeline of oral di-sulfide rich peptide (DRP) therapeutics that combine the best properties of small molecule drugs and large molecule biologics in a single chemical entity.
"The new financing will serve to support R&D efforts for the internal programs focused on well-differentiated applications of oral peptides to novel targets for diseases where neither small molecules nor biologics can currently offer a good solution," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics.
For more information, please visit Protagonist Therapeutics.
Moscow – August 09, 2013 – Inbio ventures, a management company representing Pharmstandard International S.A., has joined the Series B financing for Protagonist Therapeutics Inc., operating in Menlo Park, CA, USA, and Brisbane, Queensland, Australia.
The financing, led by Johnson & Johnson Development Corporation (JJDC), also included the participation of Series A investors Lilly Ventures and Starfish Ventures (Melbourne, Australia).The new funding will support the discovery and development of Protagonist's pipeline of oral di-sulfide rich peptide (DRP) therapeutics that combine the best properties of small molecule drugs and large molecule biologics in a single chemical entity.
"The new financing will serve to support R&D efforts for the internal programs focused on well-differentiated applications of oral peptides to novel targets for diseases where neither small molecules nor biologics can currently offer a good solution," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics.
For more information, please visit Protagonist Therapeutics.